US Has Opportunity To Lead On Ophthalmic Biosimilars
Cardinal Health’s Sonia Oskouei Expands On Findings Of 2022 Biosimilars Report And Acknowledges That Misinformation ‘Continues To Be A Challenge’
With key milestones on the horizon for US biosimilars in 2022 and 2023, Cardinal Health’s vice president of biosimilars, Sonia Oskouei, explains how the industry can best position itself to take advantage of these upcoming opportunities – including potentially a global leadership role in ophthalmology. Oskouei discusses the importance of real-world evidence and education in ensuring confidence in biosimilars, as well as the ongoing struggle against misinformation and the need for clarity over concepts such as interchangeability and unbranded biologics.
